« Return to News | CROs/Service Providers

Innovex Signs Agreement With ForceLogix For Sales Coaching Software

Friday, May 25, 2007 07:37 AM

Innovex, the Quintiles unit that provides commercialization services to the pharmaceutical, biotechnology and medical device industries, signed an agreement with software company ForceLogix to provide on-demand global access to Innsight, Innovex's custom-designed sales coaching tool.

When using ForceLogix's "SalesForceOptimizer" application, Innovex managers on six continents will be able to securely and rapidly share information to better coach their field teams.

"ForceLogix's technology allows us to deliver a multilingual coaching process that can be easily and rapidly configured and deployed globally," said Jim Kendall, senior director of Innovex Business Solutions. "This promotes the consistent execution of our coaching and enhances our ability to capture, evaluate and rank sales representative performance.”

Patrick Stakenas, president and chief executive officer of ForceLogix, added, ‘Our on-demand delivery model allows ForceLogix to quickly provide value to companies such as Innovex without the time, expense and added risks of having to buy hardware, software and implementation services.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.